Hypoxia is a prominent feature of solid tumors known to contribute to malignant progression and therapeutic resistance. Cancer cells adapt to hypoxia using various pathways, allowing tumors to thrive in a low oxygen state. Induction of new blood vessel formation via the secretion of proangiogenic factors is one of the main adaptive responses engaged by tumor cells under hypoxic conditions. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that plays a pivotal role in mediating such responses. In addition, several other transcription factors have also been implicated in hypoxic gene regulation, either independently or in cooperation with HIF-1. In this work, we show that the expression of the angiogenesis-related, immediate early gene CCN1 (formerly known as CYR61), considered to be involved in tumor growth and invasiveness, is enhanced upon hypoxia stress primarily in a protein kinase A and cyclic AMP-responsive element binding protein (CREB) and CRE -dependent manner in various cell lines. The hypoxia-mediated activation of the CCN1 promoter is independent of HIF-1 and HIF-2, as shown by small interfering RNA knockdown. We identify the cis element in the mouse CCN1 promoter responsible for CREB binding to be one of two partial CRE sites present in the promoter. Moreover, we report for the first time that CREB-mediated CCN1 transcription is enhanced in hypoxic regions of tumors in vivo. Identifying and characterizing the molecular mechanisms that govern the response of tumors to hypoxia may be instrumental to identify the tumors that will respond favorably to inhibition of angiogenesis and thus lead to the development of treatments that could complement hypoxia-inducing treatment modalities.
Introduction
Inadequate oxygen (hypoxia) triggers a multifaceted cellular response that plays a significant role in both normal physiology and pathology. The survival of developing tumors depends on the ability of the tumor cells to respond to the generation of hypoxic regions in the growing tumors. Prevention of cell death in these regions depends on angiogenesis and abrogation of apoptosis. Paradoxically, hypoxia in tumors is correlated with a worse prognosis, suggesting that the hypoxic response may provoke tumor aggressiveness (1) (2) (3) . A master regulator of this response is hypoxia-inducible factor 1 (HIF-1; refs. 2, 4-7). However, the transcriptional response to hypoxia is not limited to regulation by HIF-1 and other transcription factors such as the cyclic AMP (cAMP) responsive element-binding protein (CREB) may be involved in a tissue-specific manner, either independently or in cooperation with HIF-1 (8) (9) (10) (11) . Recently, it was reported that CREB may regulate the HIF-1 -dependent expression of the angiogenic gene, vascular endothelial growth factor (VEGF; ref. 12) .
We have previously shown that two cysteine (Cys) residues, located in the DNA binding domain of CREB, at positions 300 and 310, serve as oxygen sensors and control the binding of CREB to CRE (cAMP responsive element, TGACGTCA) sites. Moreover, we have shown that in response to hypoxia, wild-type CREB (wtCREB) increases the expression of CREB-mediated genes, whereas the CREB-mutated in cysteines at positions 300 and 310 (CREB300/310) already mimics at normoxia the increased activity of wtCREB at hypoxia (13) . We have also shown that CREB plays a pivotal role in tumor growth and angiogenesis in hepatocellular carcinoma (HCC) in vivo (10) .
The secretion of angiogenesis factors such as the fibroblast growth factor, VEGF, platelet-derived growth factor, interleukin-8, angiogenin, and CCN1, is enhanced in response to hypoxia (10, (14) (15) (16) (17) (18) (19) (20) (21) (22) . The immediate early gene CCN1 (CYR61), a member of the CCN family, codes for a secreted heparin binding protein associated with the cell surface and extracellular matrix (23) . Functionally, CCN1 promotes cell adhesion, proliferation, migration, and angiogenesis through cell type -specific binding to different integrins (24) (25) (26) (27) . Changes in CCN1 expression have been associated with several cancer types (28, 29) . CCN1 was also reported to induce migration and invasion of tumor cells (30) and a role for CCN1 has been proposed in wound healing and tumor development, two events in which hypoxia is a vital component (24) . However, the mechanisms of CCN1 transcriptional regulation are less well understood.
Activation of the human CCN1 promoter was found to be regulated by CREB and activator protein 1 (AP-1) in sphingosine-stimulated smooth muscle cells (31) and by HIF and AP-1 following hypoxia in melanoma cells (21, 22) . The mouse CCN1 promoter was found to be activated by serum components via a serum response element at position À2 kb and an Egr binding site at position À48 bp (32) (33) (34) . DNA array analysis of mouse HCC cells suggested CCN1 as one of 77 candidate genes up-regulated in response to hypoxia cue (10) .
Tumor hypoxia is associated with poor prognosis, resistance to ionizing radiation, and resistance to chemotherapy. Identifying the mechanisms through which hypoxia drives tumor progression and aggressiveness is of paramount importance. It is essential to identify specific targets that are active in hypoxic areas and facilitate tumor growth, invasiveness, and metastasis. Using a combined molecular genetic, biochemical, and immunohistochemical approach, we report here that in response to treatment with cAMP, PGE2, or hypoxia cue, CREB upregulates the expression of the mouse CCN1 gene in a protein kinase A (PKA) -dependent manner. Through promoter analysis, we define a single partial CRE in the CCN1 promoter as the binding and activation site for CREB. Knockdown of HIF-1 by small interfering RNA (siRNA) does not affect activation of CCN1 promoter by hypoxia, indicating that hypoxic activation of CCN1 is CREB dependent and HIF-1 independent. Moreover, we show for the first time that the expression of CCN1 is accentuated mostly in the hypoxic regions of tumors expressing wtCREB in contrast to tumors expressing the hypoxia-independent CREB mutant (CREB300/ 310) where CCN1 expression is enhanced and distributed evenly between the normoxic and hypoxic regions.
Taken together, our results show that CREB, a key regulator of gene expression, plays a pivotal role in the up-regulation of CCN1 in response to hypoxia in vitro and in growing tumors. Furthermore, this work highlights the role of CREB as a hypoxiaresponsive transcriptional regulator that can function independently of the known HIF-1 -or HIF-2 -dependent pathways.
Results
cAMP and Prostaglandin E2 Increase CCN1 Promoter Activity via the PKA Signal Transduction Pathway Bioinformatics analysis suggested two putative half CRE sites designated Cre1 and Cre2 at positions À801 and À64, respectively, in the CCN1 promoter region (32, 35) . As yet, no direct proof for cAMP-and CREB-mediated control of mouse CCN1 was shown. To test the effect of cAMP on activation of the CCN1 promoter, the plasmid vector, pCYRluc, harboring the CCN1 promoter from position À2062 to +65 (32, 35) , fused to the luc gene, was transfected into Rev-2-T-6 cells derived from the S49 T-cell lymphoma (36) . Following transfection, cells were treated at different times (2-24 hours) with either 8-bromo-cAMP (0.1-2 mmol/L) or with 1 to 1,000 nmol/L prostaglandin E2 (PGE2), known to elevate intracellular cAMP (37) . Luciferase activity increased in both cases in a dosedependent (data not shown) and time-dependent manner, peaking at 1.5 mmol/L of 8-bromo-cAMP or 500 nmol/L of PGE2, after 4 hours of treatment ( Fig. 1A and B) . The results depicted in Fig. 1 (C and D) show an increase in the activity of the CCN1 promoter in response to both treatments, similarly to the increase in the luciferase activity driven by a synthetic consensus CRE pGLCRE (13) . No activation of the CCN1 promoter in response to cAMP or PGE2 was detected in S49-derived KinA À cells (38) , lacking PKA activity ( Fig. 1E and F) , or in cells transfected with pGL3 in which the luc gene is driven by a SV40 promoter lacking a CRE site. The reporter assays were further validated by a reverse transcription-PCR (RT-PCR) assay of CCN1 mRNA induced by 1 Amol/L of PGE2 in serum-deprived Rev-2-T6 cells (Fig. 2) . A 10-fold increase in CCN1 mRNA levels was observed 30 minutes following induction by PGE2; the mRNA levels decreased thereafter. No changes in CCN1 mRNA levels were observed in KinA À cells (Fig. 2 ).
The differences between the two methods, Luc activity and semiquantitative RT-PCR, in the time of maximal activation of the CCN1 promoter may result from the differences in the half-life of mRNA of CCN1 relative to that of the mRNA of luciferase and/or accumulation of luciferase enzyme in the cells.
These results show that CCN1 is activated by cAMP in a PKA-dependent manner.
Regulation of the CCN1 Promoter by CREB
The activation of CCN1 by PKA suggested that the transcription factor CREB, known to be activated by PKA (39) , might be a regulator of the CCN1 promoter. To directly examine the effect of CREB on the activity of the CCN1 promoter, we constructed two stably transfected cell lines overexpressing CREB (BNL1ME and Rev-2-T6), designated Bnltc and Revtc, respectively. In these cell lines, CREB is conditionally expressed under the control of tetracycline recombinant repressor/operator. CREB was cloned in frame to FLAG tag sequence to enable detection of the recombinant protein. Western blot analysis using antibodies directed against FLAG showed that addition of doxycycline to these cell lines resulted in overexpression of CREB (Fig. 3A ). An increase of 2-and 5-fold in luciferase activity in Bnltc and Revtc, respectively, was detected following transfection of these cells with either pCYRluc or the control vector pGLCRE, in the mRNA. Rev-2-T6 cells KinA À cells were serum deprived for 16 h followed by treatment with 1 Amol/L PGE2 for the times indicated. RT-PCR products were resolved on an agarose gel and quantified. CCN1 expression was normalized to h-actin. The band presented in the middle between the Rev-2-T6 and KinA À cells was inserted as a control to show the level of CCN1 at normoxia after 35 PCR cycles. Columns, mean of three independent experiments; bars, SE. *, statistical significance at P < 0.01. presence of doxycycline relative to expression of luc mediated by the endogenous cellular CREB (Fig. 3B) . Thus, we conclude that CCN1 promoter activity is mediated by CREB.
Mutational Analysis of the CCN1 Promoter Activity in Response to Induction by cAMP, PGE2, and Overexpression of CREB To verify the functionality of the putative CRE sites in the CCN1 promoter, we carried out a set of progressive deletions and point mutations, starting at the 5 ¶ end of the CCN1 promoter region (À2062 to +65). The mutated promoters were fused to the luc gene in the plasmid vector pGL3basic (Promega) and analyzed in two cell lines. Activation of Luc expression mediated by the various deletion mutants was analyzed in transfected Rev-2-T6 cells following treatment with either 8-bromo-cAMP or PGE2. Activation of the various deletion and point mutational CCN1 promoter constructs by overexpression of CREB from a cotransfected pwtCREB plasmid vector (10) was monitored in HEK293 because transfection efficiencies in Rev-2-T6 cells are low. However, independently of cell type and type of promoter activation, the results indicate that only one functional CRE site is located in the mouse CCN1 promoter region at position À64 from the transcription start site. Luciferase activity in all experiments was normalized to the activity of Renilla luciferase expressed from the SV40 promoter (pRLSV40, Promega), which was not affected by treatment of the cells with cAMP, PGE2, or CREB.
Deletions extending to À801, devoid of the serum response element and CRE1 consensus sequences (Fig. 4A) , abrogate the serum response (not shown) but barely affected the stimulation of luciferase expression by cAMP or PGE2 relative to the full promoter (Fig. 4B) . However, deletion of the region spanning the promoter region located between the AatII and NarI restriction sites (position À801 to À46), including the Cre2 site, abolished by more than 99% luciferase activity in response to cAMP and PGE2 (Fig. 4B) . Similar results were obtained when the various promoter constructs were cotransfected with the CREB-expressing vector pCREBwt into HEK293 cells (Fig. 4B) . Based on these results, we mutated specifically the two putative CRE sites, Cre1 and Cre2, giving rise to plasmids pCre1m and pCre2m, respectively (Fig. 4A ). In accordance with the deletion mapping, mutation in Cre1 had no effect on CREB-mediated expression, whereas a point mutation in Cre2 site of the CCN1 promoter abolished CREB-mediated luciferase expression in response to cAMP, PGE2, or overexpression of CREB (Fig. 4B) . Thus, the Cre2 site in the CCN1 promoter is essential for promoter activity. CCN1 promoter was designated À2062 (À2062 to +65). The deletions and mutations in the CCN1 promoter are indicated as À1413 (À1413 to +65), À801 (À801 to +65), and DNru IAat II (removal from À1413 to À801). In DAat IINar I, a DNA fragment extending from À801 to À44 was removed. DNru INar I is deleted from À1413 to À44. Cre1m, Cre2m, and Credm were constructed as described (Materials and Methods). The relative expression of luciferase in Rev-2-T6 cells, transfected with the various CCN1-luc promoter-constructs and induced with either 8-bromo-cAMP (open columns ) or PGE2 (filled columns ), are depicted on the right side. The effect of the overexpression of CREB in HEK 293T cells transiently cotransfected with CREB-expressing vector and each of the CCN1-luc promoter constructs is depicted on the right side (striped columns ). All results were normalized to renilla luciferase activity, which was not affected by the different treatments and to the activity of the À2062 vector set as 100%. Columns, mean of three independent experiments done in triplicates; bars, SE. *, significant increase relative to pCYRluc-transfected control untreated cells (P < 0.01). #, significant decrease relative to pCYRluc-transfected cells treated with cAMP/PGE2 or cotransfected with CREB (P < 0.01).
CREB-Mediated Regulation of CCN1 Gene Expression in Response to Hypoxia
We have previously found by DNA microarray analysis that CCN1 is one of a group of angiogenesis genes that are up-regulated in response to hypoxia (10) . Furthermore, CCN1 expression is increased in tumors (24) . Because hypoxia is also a feature of tumor development, we set out to further elucidate the molecular mechanisms underlying enhanced CCN1 gene expression under hypoxia. We monitored the effect of hypoxia (1% oxygen concentration) on luciferase expression controlled by the CCN1 promoter. The results presented in Fig. 5A clearly show that hypoxia significantly induced CCN1 promoter activity in Rev-2-T6 cells (f2.5-fold), whereas no effect of hypoxia was noticed when the luc gene expression was controlled by the CCN1 promoter mutated in Cre2 (Fig. 5A ). It is noteworthy that the Cre2 mutation significantly decreased the expression of luciferase also at normoxia (Fig. 5A ), suggesting dependence of the CCN1 promoter on CREB. When the same analysis was carried out in KinA À cells, no hypoxia-mediated increase in CCN1 promoter activity was detected (Fig. 5B ).
CCN1 Promoter Activation Is CREB Dependent and HIF-1 and HIF-2 Independent
To examine the possible involvement of HIF-1 and HIF-2 in the activation of the mouse CCN1 promoter, we carried out knockdown experiments targeting HIF-1 and HIF-2 in mouse NIH3T3 cells. It should be noted that HIF-1 was activated in KinA À cells under hypoxia because Luc activity increased when driven by a HIF-1 -responsive promoter following transfection of the cells with the reporter vector pHREluc, where luciferase is under the control of hypoxia responsive element (HRE; Fig. 5B ). These results suggest that although HIF-1 is activated in response to hypoxia in both cell lines in our experimental design, it does not activate the CCN1 promoter. This conclusion was further verified by knockdown of HIF-1 and HIF-2 by siRNA, carried out in murine NIH3T3 cells. The cells were transfected with siRNA targeting either HIF-1 or HIF-2 and placed under hypoxic conditions. Western blot analysis of the cell extracts using anti HIF-1a or anti HIF-2a antibodies showed knockdown of HIF-1a and HIF-2a, respectively (Fig. 6A ). Luciferase activity controlled by HRE, in the control vector (pHREluc), was significantly reduced by HIF-1 siRNA at hypoxia and less by HIF-2 siRNA ( Fig. 6B ), indicating that the HIF-1 is mostly responsible for HRE-mediated transcription at hypoxia. However, the results presented in Fig. 6C clearly show that knocking down either HIF-1 or HIF-2 had no effect on the activation of CCN1 promoter by hypoxia. A scrambled siRNA (siScr) was used as a negative control for siRNA specific activity. These results further indicate that the CCN1 promoter is activated at hypoxia independently of HIF-1 and HIF-2.
The hypoxia-mediated activation of CCN1 promoter by CREB was further shown by abrogation of the activation of the CCN1 promoter by the dominant negative CREB, A-CREB (40) . These results prove that the mouse CCN1 promoter activity at hypoxia is mediated by CREB and not by either HIF-1 or HIF-2.
Activation of Endogenous CCN1
The activation of the native CCN1 promoter in its natural chromosomal location was monitored by a RT-PCR assay of CCN1 mRNA induced by hypoxia. The results presented in Fig. 6D show that similar to the experiments using reporter vectors (Fig. 6C) , the increased CCN1 expression at hypoxia was not affected by either siHIF-1 or siHIF-2 but was significantly reduced when cells were transfected with the dominant negative A-CREB.
Based on the results presented, it was tempting to address the possibility that hypoxia-mediated CCN1 expression uses the PKA-CREB signal transduction pathway. To that effect, Rev-2-T6 cells and KinA À cells were cultured at normoxic or hypoxic conditions (for 8 and 16 hours). Changes in phosphorylated CREB (pCREB) and CCN1 mRNA were determined by Western blot analysis and RT-PCR, respectively ( Fig. 7A and B) . As a control for hypoxia, we used Glut-1, which is known to be induced at hypoxia (41) and was indeed elevated in both cell lines (Fig. 7C) . A significant increase in pCREB relative to total CREB was observed following exposure of Rev-2-T6 cells to hypoxia, whereas only a slight increase in pCREB was detected in the KinA À cells (Fig. 7A) . The increase in phosphorylated CREB was in correlation with the increase in CCN1 mRNA in response to hypoxia (Fig. 7B) . No increase in CCN1 mRNA in KinA À cells was observed. Next, we checked for changes in the amount of CCN1 protein in response to hypoxia. Because CCN1 Luciferase assays were normalized to Renilla luciferase activity. Columns, mean of three independent experiments done in duplicates; bars, SE. *, significant increase in luciferase activity; #, significant decrease in both basal activity and hypoxia induced activity (P < 0.01).
is a secreted protein and is active as such, we monitored the amount of the CCN1 protein in conditioned medium from an equal number of Rev-2-T6 or KinA À cells cultivated at either normoxia or hypoxia for 16 hours. Conditioned medium was concentrated (see Materials and Methods) and the amount of CCN1 protein was determined by Western blot analysis (Fig.  7D) . The results show a 7.3-fold increase in secretion of CCN1 protein from Rev-2-T6 cells cultivated for 16 hours at hypoxia relative to normoxia. No difference in the secretion of CCN1 from KinA À cells cultivated at either hypoxia or normoxia was observed (Fig. 7D ).
Taken together, our results show that the PKA-CREB signaling pathway plays a role in the activation of CCN1 in response to hypoxia.
Hypoxia Increases the Binding of CREB to CRE in the CCN1 Promoter
The results presented thus far suggest an important role for the Cre2 site in hypoxia-stimulated CCN1 gene transcription. To further corroborate these findings, purified recombinant CREB and nuclear extracts from cells grown at hypoxia were incubated with double-stranded oligonucleotides corresponding to the CRE2 region of CCN1 and analyzed by electrophoretic mobility shift assay. The results presented in Fig. 8 show that CREB interacts with the Cre2 site of CCN1 (Fig. 8A, lane1 , and B, lane 1). The binding efficiency is further increased when CREB originated from cells incubated at hypoxia (Fig. 8B, lane 2) . The DNA/CREB complexes were further supershifted when antibodies directed against CREB were added to the reaction (Fig. 8B, lane 6) . Competition with either nonlabeled CRE or Cre2 oligonucleotides (in 10 and 50 mmol/L excess) significantly reduced the binding of CREB to the probes in a dosedependent manner (Fig. 8A, lanes 2-5, and B, lanes 3 and 4) . Oligonucleotides mutated in Cre2 failed to compete for CREB binding (Fig. 8A, lanes 6 and 7) . No binding was detected when a 32 P double-stranded oligonucleotide mutated in Cre2 was used (Fig. 8A, lane 9 , and B, lane 5 ) . It is noteworthy that no increase of total CREB was detected in hypoxic cells (Fig. 7A) .
CREB Mediates CCN1 Expression in Tumors in Response to Hypoxia
The results presented thus far show that CCN1 expression in vitro is enhanced in response to hypoxia in a CREB-dependent B. Luciferase activity in cell extracts of NIH3T3 cells transfected with either siHIF or siScr together with pHREluc reporter plasmids at normoxia or hypoxia (16 h). C. Luciferase activity in cell extracts of NIH3T3 cells transfected with siHIF, siSCR, empty vector, or dominant negative A-CREB together with pCYRluc. D. RT-PCR products of NIH3T3 cells, exposed to hypoxia, were resolved on an agarose gel and quantified. CCN1 expression was normalized to h-actin. Columns, mean of three independent experiments; bars, SE. *, significant increase in luciferase activity or CCN1 mRNA expression relative to normoxic cells (N ). #, significant decrease in luciferase activity or CCN1 mRNA expression at hypoxia-treated cells (H ) relative to siScr (when comparing siRNA) or relative to empty vector -transfected cells when comparing A-CREB (P < 0.01).
manner. To evaluate whether CREB is involved in the regulation of CCN1 in response to hypoxia cue in tumors, sections from six HCC BNL1ME tumors overexpressing wtCREB were stained for hypoxia, followed by in situ hybridization of consecutive sections for the detection of CCN1 mRNA (see Materials and Methods). The results indicate that the expression of CCN1 is localized mostly in the hypoxic regions (Fig. 9A, top panels) . The expression of CCN1 in tumors (six) overexpressing the hypoxia-independent CREB300/310 mutant, previously shown to mimic at normoxia the activity of wtCREB at hypoxia (10), was enhanced and evenly distributed between the normoxic and hypoxic regions (Fig. 9A, bottom panels) . It is noteworthy that no staining was observed in sections from tumors not injected with hypoxyprobe or tumors hybridized with the sense strand of CCN1 (not shown). A quantitative analysis of CCN1 expression in the tumor sections, by an Ariol SL50 automated image analyzer (see Materials and Methods), shows that the total expression of CCN1 in tumors overexpressing CREB300/310 was 2.7-fold higher than in tumors overexpressing wtCREB (P = 0.001) and 3.5-fold higher (P = 0.0069) in normoxic regions compared with normoxic regions in wtCREB-overexpressing tumors (Table 1 ). In addition, CCN1 mRNA was more abundant in the hypoxic regions than in the normoxic regions of tumors expressing wtCREB (3.6 fold, P = 0.0083), whereas no correlation between CCN1 and hypoxic regions was noted in tumors expressing CREB300/310 (1.2 fold, P = 0.3062; Table 1 ). These results suggest that CREB plays a significant role in the activation of CCN1 in response to developing hypoxia in growing tumors.
Discussion
Rapidly growing tumors and tumor metastases are exposed to ongoing hypoxic conditions in the tissue microenvironment. Hypoxia, in turn, has a profound influence on tumor pathophysiology. The survival of the tumor and its aggressiveness depend on its ability to respond quickly to hypoxia cues. Cells undergo a variety of biological responses when placed under hypoxic conditions, including activation of signaling pathways that regulate proliferation, angiogenesis, and death (1-3). Cancer cells have adapted these pathways, allowing tumors to survive and even grow under hypoxic conditions (2). Although tissue hypoxia is a well-documented phenomenon, our understanding of the response of tumor cells to hypoxia is far from being complete. The response to hypoxia may be divided into two mechanisms: the first one sensing the level of oxygen and the second one activating the hypoxia-induced genes, some of which contribute to tumor angiogenesis. A large body of evidence accumulated with regard to the role of the hypoxia-induced factors, HIFs, as activators of hypoxiaresponding genes (2, 4, 5, 42) . The significance of HIF-1 and HIF-2 contribution to tumor growth is well documented (for review, see ref. 6 ). Previously, we have shown that the redox state of two cysteine residues, located at the DNA binding domain of CREB, regulates the binding efficiency of CREB to CRE (13) and the expression of f77 genes in response to hypoxia (10) . Thus, CREB may serve as a sensor of hypoxia and an activator of hypoxia-responding genes (10) .
Among the genes that we found to be regulated at hypoxia by DNA array analysis, we identified the angiogenesis gene CCN1 whose secreted protein contributes to cellular proliferation, differentiation, and angiogenesis (25) (26) (27) . CCN1 expression is elevated in a range of tumors (24) . Furthermore, CCN1 contributes to cell proliferation and tumor growth. However, the mechanisms governing the expression of CCN1 in tumors remain poorly defined. Because hypoxia is also a feature of tumor development, we became interested in the mechanism by which hypoxia up-regulates CCN1 expression. A greater understanding of the molecular mechanisms by which tumor hypoxia increases CCN1 expression will identify novel therapeutic windows of opportunity.
In this study, we have shown that CREB positively regulates the expression of CCN1 in response to hypoxia in vitro and activates CCN1 gene expression in correlation with hypoxic regions in tumors in vivo. We show that the CCN1 promoter is activated by either cAMP or following treatment with PGE2, which elevates the internal pool of cAMP in the cells (37) . PGE2 is known to promote tumor growth, angiogenesis, and cell migration and to up-regulate VEGF (43) . Interestingly, PGE2 was recently found to be activated by CCN1 (30) . Thus, the mutual activation may point toward a feedback mechanism between PGE2 and CCN1.
Furthermore, we show that activation of the mouse CCN1 promoter by CREB is PKA dependent. No CCN1 promoter activity was detected in KinA À cells, lacking PKA activity in response to either cAMP, PGE2, or hypoxia (Figs. 1 and 5 ). Several signal transduction pathways such as RhoAGTPase, p38MAPK, CaM kinase IV, and PKC have been implicated in the response to stress signals such as hypoxia (31, 44, 45) . It is noteworthy that another CCN family member, CCN2, was found to be suppressed by cAMP due to inhibition of the activity of mitogen-activated protein kinases (46) . These results suggest that CCN1 and CCN2 may both be regulated through the cAMP signal transduction pathway: CCN1 is activated whereas the other, CCN2, is suppressed. The differences in response to cAMP may also derive from the different cell lines used in these experimental systems.
In this work, we show for the first time that in response to hypoxia, CREB is phosphorylated by PKA. Interestingly, it was shown that the angiogenesis-related gene, VEGF, is also activated by the PKA/CREB pathway at normoxia (47) . However, whereas VEGF is regulated by both HIF-1 and CREB in response to hypoxia (12), we show here that CCN1 is HIF-1 independent.
Bioinformatics analysis of the mouse CCN1 promoter pointed out several regulatory sites, such as a serum response element and two Sp1 and two CRE sites at positions À804 and À64 from the transcription start site (32) . By further analysis, we revealed that the mouse promoter harbors one putative HRE-like site at positions À965 and four inverted HRE like sites at positions À50, À303, À912, and À1086. Previously, Kunz et al. (23) revealed by a mutational analysis that the four inverted HRE-like sites at positions À68, À371, À400, and À653 in the human CCN1 promoter are not active in response to hypoxia. Using deletion and point mutation analyses, we revealed, for the first time, that only one CRE site (Cre2), at position À64 on the mouse 2,062-bp-long CCN1 promoter, functions as a CREB binding and activation site. Mutating the Cre2 site abolished the binding (Fig. 8) and the response to cAMP, PGE2, or overexpression of CREB (Fig. 4) . This Cre2 site in the mouse CCN1 promoter is homologous to that of the active Cre3 site in the human CCN1 promoter, located at position À29 from the TATA box (31) . Not surprisingly, the mutation in Cre2 also decreased basal promoter activity because CREB is known to be involved in basal transcription as well (48) .
Like other angiogenesis factors, the expression of CCN1 is elevated in response to hypoxia (Figs. 5 and 6 ). Our experiments revealed, for the first time, that the CCN1 promoter is activated at hypoxic conditions mostly via CREB/Cre2 interaction in a PKA-dependent manner. The hypoxia-induced activation of the CCN1 gene was greatly reduced by a mutation in CRE 2 (pCre2m), proving that CRE2 is essential for CCN1 hypoxic induction. Activation of the human CCN1 promoter in melanoma cells was found to be regulated by HIF-1 and AP-1 following hypoxia (21, 22) . The knockdown of HIF-1 and HIF-2 in our experimental design did not affect the activation of the mouse CCN1 promoter at hypoxia (Fig. 6) . Knockdown of the HIF-1 in human HEK293T cells did not affect the activation of the mouse CCN1 promoter at hypoxia (not shown). However, the activity of the CYR promoter at hypoxia was abrogated in the KinA mutant cells, which lack PKA activity that is essential for CREB function. Moreover, the hypoxia response of the CCN1 promoter (located either on the expression vector or in its native location on the chromosome) was abrogated in cells transfected with the dominant negative A-CREB. No upregulation of the CCN1 RNA was detected in the presence of the A-CREB in response to hypoxia cue (Fig. 6) . Thus, in accordance with the knockdown of HIF-1 and HIF-2, this experiment indicates that the activation of the CCN1 promoter at hypoxia is mostly controlled by CREB and not by HIFs. Interestingly, the activation of CCN2 in response to hypoxia is still under debate. Higgins et al. (49) show that HIF-1 is involved in the transcriptional activation of CCN2 at hypoxia, The in situ hybridization for CCN1 expression of sections from six tumors of each type (wtCREB and CREB300/310) was quantified by an automated image analysis system (see Materials and Methods) and the proportion of CCN1-positive area was calculated for the total expression of CCN1 and for normoxic and hypoxic regions, determined by hypoxyprobe staining, of each tumor type. The results presented are the means F SE expressed in % stained areas. The % of hypoxic regions was 16 F 1 in wtCREB tumors and 28 F 3 in CREB 300/310 tumors. The statistical significance when comparing % CCN1 expression between wtCREB and CREB300/310 is P = 0.001; when comparing normoxic regions between the two tumor types (second column), the statistical significance is P = 0.0069. *Statistical significance when comparing normoxic with hypoxic regions in tumors expressing wtCREB (P = 0.0083). cNo statistical significance was observed when comparing normoxic with hypoxic regions in CREB300/310 tumors. identified by immunohistochemistry (brown staining, left panels ). Consecutive tissue sections were assayed for CCN1 expression by mRNA in situ hybridization (blue staining, middle panels ) and counterstained by nuclear fast red. An overlay of hypoxia (red dotted line ) and CCN1 (yellow dotted line ) is presented (right panels ). B. Slides were subjected to automated image analysis that assigned a positive or negative value for the CCN1 staining for each pixel. The photomicrograph (right ) shows an example of areas determined by the computer to be positively stained (green ) or negative areas (pink), marked by arrows as + or À, respectively. Left, CCN1 staining (blue ) before the computer analysis.
whereas Kondo et al. (50) show that the CCN2 activation at hypoxia is at the posttranscriptional level and a result of increased mRNA stability during hypoxia probably through a HIF-1 -independent pathway. An AP-1 site was found to be involved in the activation of the human CCN1 promoter in response to hypoxia (22) . This AP-1 site is not conserved in the mouse promoter. It is conceivable that different mechanisms are involved in the response of the two promoters to hypoxia, yet other studies indicate that CREB may bind to AP-1 sites, which differ in only one nucleotide from the consensus CRE (51) . The enhanced binding of CREB to Cre2 and up-regulation of the CCN1 promoter activity in Rev-2-T6 cells at hypoxia is in correlation to the PKA-dependent persistent phosphorylation (for at least 16 hours) of CREB and consequent increased levels of CCN1 mRNA following hypoxia (Fig. 7) . The enhanced secretion of CCN1 protein (Fig. 7D) further supports the functional relevance of CCN1 following hypoxia-mediated PKA-CREB pathway. This suggests that phosphorylation of CREB and activation of a subset of hypoxiaresponsive genes may be an adaptive cellular response to a reduction in O 2 levels. Our results are in accordance with other studies that report increased sustained phosphorylation of CREB in response to hypoxia (11, 35, 48, 52) .
However, because some studies show that the binding of CREB to CRE is phosphorylation independent (53), the increase in phosphorylated CREB cannot account by itself for the robust increase in the binding of CREB from cells grown at hypoxia to the Cre2 site. It seems rather that under hypoxic conditions, CREB binds more efficiently to its target DNA sites and together with the elevated level of phosphorylated CREB leads to an increase in CREB-mediated expression of genes such as CCN1. These results are in accordance with our previous findings that under hypoxic condition, the disulfide bonds between the two Cys residues in the CREB DNA binding domains are not generated, resulting in a more efficient binding of CREB to DNA (10, 13) . Taken together with the enhanced PKA-dependent phosphorylation of CREB at hypoxia (Fig. 6) , we conclude that these two modifications of CREB are important mediators of CREB activity in tumors in response to hypoxia.
The in vitro data demonstrating CREB-mediated regulation of CCN1 at hypoxia suggested that in tumors, CCN1 may be expressed preferentially in hypoxic regions. Indeed, the results presented in Fig. 9 and Table 1 show that CCN1 is expressed mostly in the hypoxic regions of growing tumors expressing wtCREB, whereas no correlation between the expression of CCN1 to the hypoxic regions was noticed in tumors expressing the hypoxia-independent CREB300/310 mutant (Fig. 9) . These results indicate that the angiogenesisrelated gene CCN1 is activated by CREB, in response to hypoxia, in the growing tumor. Taken together, we conclude that CREB plays a significant role in response to developing hypoxia in tumors by up-regulating angiogenesis genes such as CCN1.
To date, no experimental work has shown a hypoxiamediated activation of CCN1 by CREB in growing tumors. These novel findings validate and give significance to the in vitro data accumulated thus far by us as well as others, having both mechanistic as well as therapeutic implications.
In this study, we investigated one of the many molecular mechanisms of cellular response to hypoxia, involving CREBmediated transcriptional activation of the angiogenesis gene CCN1, which is known to be involved in tumorigenesis and angiogenesis. Additional studies are needed to further understand potential mechanisms that regulate CCN1 expression and to evaluate both CREB and CCN1 as potential targets for cancer therapy.
Materials and Methods

Cells and Materials
Cells. Rev-2-T6 (PKA + ) and KinA À cells were derived from the S49 BALB/c T-cell lymphoma, a unique model system for exploring various parameters affected by the cAMP/PKA pathway (36, 38, 54, 55) . The KinA À cells are commonly used as a PKA-deficient cell line (55) (56) (57) .
The murine HCC and the BNL1ME A.7R.1 cell lines were previously described (10) . NIH3T3 fibroblasts were used in the siRNA knockdown experiments. Induction of CREB was carried out by 8-bromo-cAMP, PGE2, and doxycycline (Sigma). BNL1ME cells stably expressing the CREB variants, wtCREB, and CREB300/310 (10) were used for in vivo experiments. All cell lines were grown in DMEM supplemented with 10% FCS, 2 mmol/L glutamine, and 100 units/mL penicillin-streptomycin (Biological Industries).
Transfections. Rev-2T6, KinA À , NIH3T3, and BNL1ME cells were transfected using Transfast (Promega). HEK293 cells were transfected using Profection mammalian transfection kit (Promega).
Construction of Conditional Expressing CREB Stable
Clones BNL1ME and Rev-2-T6 cells were transfected with the transactivator rtTA of the Tet-on system (58) and the hygromycin-resistant gene, a kind gift from H. Hauser (Braunschweig, Germany). Stable clones were selected with hygromycin (200 Ag/mL). To generate tetracycline-regulated CREB expression plasmid, the CREB gene was inserted into the NdeI/BamHI sites of FLAG-tagged coupled tetracyclineinducible expression vector pTetCMV-F0(S) (ref. 59) , kindly provided by Dr. Cheng-Ming Chiang (University of Illinois at Urbana-Champaign, IL) and cotransfected with pBABE harboring puromycin resistance gene into BNL1ME and Rev-2-T6 cells. Stable clones were selected with puromycin (2 Ag/mL). CREB-expressing cell lines were designated Bnltc and Revtc, respectively.
Western Blot Analysis
Bnltc and Revtc cells were treated with doxycycline (2 Ag/mL, 24 h) and lysed in radioimmunoprecipitation assay buffer with protease cocktail (Sigma). Samples (20 Ag) were separated by 10% SDS-PAGE and transferred to nitrocellulose. CREB was visualized using anti -Flag M2 antibody (Sigma) followed by goat anti-mouse horseradish peroxidase antibody (Sigma) and detected by enhanced chemiluminescence (Amersham). Antibodies against pCREB (phosphorylated at Ser 133 ), CREB (Cell Signaling), and goat anti-rabbit horseradish peroxidase antibody (Sigma) were used for Western blot of Rev-2-T6 and KinA À cells, cultivated at either normoxia or hypoxia. Quantification of band intensity was done using Image master VDS-CL (Amersham). HIF-1a was visualized by a rabbit anti -HIF-1a antibody (Novus Biologicals); HIF-2 was visualized by a rabbit anti -HIF-2 antibody (Novus Biologicals); Glut-1 was visualized by a rabbit anti -Glut-1 antibody (Chemicon). CCN1 protein from conditioned medium of Rev-2-T6 or KinA À cells (430,000 cells), concentrated 15Â using Amicon Ultra-4 filter devices (Millipore) was visualized by a rabbit anti-CCN1 antibody (Santa Cruz Biotechnology).
Deletions and Mutations of the CCN1 Promoter
The CCN1 promoter region (nt À2062 +65) was cut out from the 2LACZ vector (60), a kind gift from Dr. Lester Lau, Department of Biochemistry and Molecular Genetics, University of IL, Chicago, IL, by cleavage with XhoI and inserted into pGL3-basic missing a promoter for the luc gene (Promega), generating pCYRluc. Cre1m was generated by deleting the ACGT bases from the CRE1 site GACGTCA. Cre2m was generated by changing TACGTCA to TAAACCA using the following mutating primers: 5 ¶-CGCTAGTGTCGC-GAAGCTGCAAAGGC-3 ¶ an d 5 ¶-GCGTAGCTG G-CGCCGCGTGTTGCAGTGGTTTAGC-3 ¶. Credm is mutated in both CRE sites. Deletions and point mutations are indicated in Fig. 4 and were verified by DNA sequencing.
Luciferase Assay
CCN1 promoter -mediated luciferase expression was determined in transiently transfected cell lines with the reporter plasmid pCYRluc, exposed to either 8-bromo-cAMP or PGE2. Similarly, the activation of the CCN1 promoter was monitored in cells overexpressing CREB or grown at hypoxic conditions. Reporter vector pHRE-luc, harboring four HREs mediating the luc gene (a kind gift from Dr. Yuval Dor, Department of Biochemistry and Genetics, the Hebrew University, Jerusalem, Israel), was transfected to Rev-2-T6 and KinA À cells and luciferase activity was measured in response to hypoxia. Bnltc and Revtc cells (see above) were transfected with either pCYRluc or pGLCRE harboring a synthetic somatostatin CRE mediating the luc gene expression (13) . Plasmid phRLSV40 (Promega) was used as a transfection control in all luciferase experiments. Luciferase activity was determined according to the manufacturer's instructions (Dual Luciferase Kit, Promega). Light emission was monitored 48 h after transfections by an automatic Mithras LB 940 photoluminometer (Berthold Technologies).
siRNA Transfection Assay Double-stranded siRNA specific for HIF-1, 5 ¶-CUAACUG-GACACAGUGUGUUU-3 ¶ and 5 ¶-ACACACUGUGUCCA-GUUAGUU-3 ¶, was purchased from Dharmacon Research, Inc. siRNA specific for HIF-2 was purchased from Santa Cruz Biotechnology (sc-35317). The siRNA (100 nmol/L) was transfected using Lipofectamine 2000 reagent, according to the manufacturer's instructions (Invitrogen). A siScr sequence (Dharmacon Research) was used as a nonspecific control. The siRNA was transfected together with plasmids pCYR-luc and pHRE-luc. As a transfection control, we used plasmid pRLTK (Promega). Twenty-four hours posttransfection of NIH3T3, the cells were either exposed to hypoxia (16 h) or left under normoxic conditions. The cells were lysed and the luciferase activity was determined. For Western blot experiments, cells were seeded on six-well plates, transfected with siRNA, and placed at hypoxia. Western blotting for detection of HIF-1a was done as described.
RNA Isolation, Reverse Transcription, and PCR
Rev-2-T6 and KinA À cells were serum deprived for 16 h followed by addition of PGE2 (1 Amol/L) for 30 min, 2 h, and 4 h. Both cell lines were exposed to hypoxia (8 and 16 h). Total RNA was extracted using SV total RNA purification kit according to the manufacturer's instructions (Promega). RNA was quantified and 1 Ag was used for cDNA synthesis with the ImProm-II Reverse Transcription System (Promega). One microliter of cDNA from the reverse transcription reaction was added directly to a 25 AL PCR mix. Reaction conditions were as follows: 94jC, 60jC, and 72jC. CCN1 was amplified for 30 or 35 cycles, and h-actin was amplified for 25 cycles. CCN1 primers: 5 ¶-ATTGGAAAAGGCAGCTCACTGA-3 ¶ and 5 ¶-GGATTTCTTGGTCTTGCTGC-3 ¶, fragment size 280 bp. hActin primers: 5 ¶-ACCAACTGG GACGATATGGAGAAGA-3 ¶ and 5 ¶ TACGACCAGAGGCATACAGGGACAA-3 ¶, fragment size 216 bp. Reverse transcription conditions were established so that the RNA was not limiting and the PCR amplification reaction was stopped in the linear range. PCR products were identified by size after electrophoresis on a 2% agarose gel and band intensity was quantified using image master VSD-CL (Amersham). CCN1 mRNA levels were normalized to the levels of h-actin mRNA.
Electrophoretic Mobility Shift Assay
His-tagged CREB recombinant protein was purified using the Magnehis protein purification system (Promega). Nuclear extracts from cells exposed to hypoxia (16 h) were prepared as described (61) . The following oligonucleotides were annealed and used as a probe [derived from CCN1 promoter region including the putative Cre2 binding sequence (underlined)]: 5 ¶-GATCCCGACAGAGCTACGTCACTGCAACACG-3 ¶ and 5 ¶-GATCCGTGTTGCAGTGACGTAGCTCTGTCGG-3 ¶. The following oligonucleotides mutated in Cre2 were used: 5 ¶-GATCCCGACA GAGCTAAACCACTGCAACACG-3 ¶ and 5 ¶-G ATCCGTGTTGCAGTGGTTTAGCTCTGTCGG-3 ¶. As a control, a commercial double-stranded CRE consensus oligonucleotide (Promega) was used. The DNA probes were labeled with [g 32 P]CTP at the 3 ¶ end by filling the sticky ends with DNA polymerase large fragment (Klenow). Electrophoretic mobility shift assay was done in a 20 AL reaction mixture containing 20 mmol/L HEPES (pH 7.5), 50 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 1 mmol/L DTT, 1 mmol/L EDTA, 10% glycerol, 1 mg poly(deoxyinosinic-deoxycytidylic acid), 50 fmol radiolabeled probe (50,000 cpm), with 1 Ag of recombinant CREB protein or 10 Ag of nuclear proteins. The protein/DNA complexes were subjected to gel electrophoresis on a 5% nondenaturing polyacrylamide gel in 0.5% Tris-borate EDTA buffer.
Monoclonal anti-CREB antibody (Cell Signalling) was used for the supershift analysis. Gels were dried at 80jC for 1 h and exposed to Hyperfilm (Amersham) at À70jC.
Animal Protocol
BALB/c mice (6 wk old, 20-g body weight) were implanted subcutaneously in the lower back with 10 6 HCC, BNL1ME, stably transfected with one of the CREB variants-wtCREB or CREB300/310 (6 mice per group). The studies conformed to the principles for laboratory animal research and were approved by the Hebrew University Animal Care and Use Committee. Mice were sacrificed 30 d postinoculation.
Immunohistochemistry of Tumor Sections
To identify hypoxia regions in the tumors, Hypoxyprobe-1 Plus Kit was used (Chemicon). The kit uses pimonidazole hydrochloride as a specific marker for detecting hypoxic cells. Hypoxyprobe-1 was administered i.p. (60 mg/kg) 30 min before sacrificing the mice and tumors were excised (6 tumors expressing either wtCREB or CREB300/310). Tumors were formalin fixed and paraffin embedded. After tissue sectioning, slides were deparaffinized, rehydrated, and heated in100 mmol/L glycine buffer (pH 9) in a pressure cooker at 115jC. Tissue sections were incubated with the primary antibody, Hypoxyprobe-1 Mab-1 (mouse IgG1), 1:100, in CAS-Block (Zymed) overnight followed by 30-min incubation with anti-mouse Envision (Dako) and developed with 0.025% 3,3 ¶-diaminobenzidine (Dako) according to the manufacturer's recommendations. As control for antibody specificity, sections from tumors excised from mice not injected with the hypoxyprobe were reacted with the antibody.
In situ Hybridization of Tumor Sections
Plasmid PYX-Asc harboring the CCN1 cDNA clone (Geneservice Ltd.) was linearized by either EcoRI or NotI. Sense and antisense RNA probes were synthesized by in vitro transcription of the DNA template with T3 and T7 RNA polymerases and labeled by DIG-labeling mix (Roche). The T7 RNA polymerase was used to synthesize the equivalent sense transcript and served as a negative control for hybridization. Whole-mount in situ hybridization on tumor sections was done essentially as described (62) . Antibodies combined with alkaline phosphatase were used for detection. Slides were counterstained with Nuclear Fast Red (Sigma). Quantitative analysis was done using a robotic automated image analysis system (Ariol SL50, Applied Imaging) as previously described (63) . For each tumor, the entire tumor section was scanned. A threshold for blue staining was arbitrarily determined and used to assign a positive or negative value for each pixel of each tumor, and the percentage of positive area was calculated for the entire section or for hypoxic and normoxic areas, determined by hypoxyprobe staining.
Statistical Analysis
All data are presented as mean F SE. Student's t test was used to analyze differences between the two groups; multiple comparisons among the different CCN1 promoter mutants were done by applying one-way ANOVA with Dunnett's posttest. P values <0.05 were considered significant.
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